@article{oai:hirosaki.repo.nii.ac.jp:00005475,
 author = {Hosogoe, Shogo and Hatakeyama, Shingo and Kusaka, Ayumu and Hamano, Itsuto and Tanaka, Yoshimi and Hagiwara, kazuhisa and Hirai, Hideaki and Morohashi, Satoko and Kijima, Hiroshi and Yamamoto, Hayato and Tobisawa, Yuki and Yoneyama, Tohru and Yoneyama, Takahiro and Hashimoto, Yasuhiro and Koie, Takuya and Ohyama, Chikara},
 issue = {30},
 journal = {ONCOTARGET},
 month = {Jul},
 note = {Background and Objective: A quantitative tumor response evaluation to molecular-targeting agents in advanced renal cell carcinoma (RCC) is debatable. We aimed to evaluate the relationship between radiologic tumor response and pathological response in patients with advanced RCC who underwent presurgical therapy. 

Results: Of 34 patients, 31 underwent scheduled radical nephrectomy. Presurgical therapy agents included axitinib (n = 26), everolimus (n = 3), sunitinib (n = 1), and axitinib followed by temsirolimus (n = 1). The major presurgical treatment-related adverse event was grade 2 or 3 hypertension (44%). The median radiologic tumor response by RECIST, Choi, and CMER were -19%, -24%, and -49%, respectively. Among the radiologic tumor response tests, CMER showed a higher association with tumor necrosis in surgical specimens than others. Ki67/MIB1 status was significantly decreased in surgical specimens than in biopsy specimens. The magnitude of the slope of the regression line associated with the tumor necrosis percentage was greater in CMER than in Choi and RECIST. 

Materials and Methods: Between March 2012 and December 2016, we prospectively enrolled 34 locally advanced and/or metastatic RCC who underwent presurgical molecular-targeting therapy followed by radical nephrectomy. Primary endpoint was comparison of radiologic tumor response among Response Evaluation Criteria in Solid Tumors (RECIST), Choi, and contrast media enhancement reduction (CMER). Secondary endpoint included pathological downstaging, treatment related adverse events, postoperative complications, Ki67/MIB1 status, and tumor necrosis. 

Conclusions: CMER may predict tumor response after presurgical moleculartargeting therapy. Larger prospective studies are needed to develop an optimal tumor response evaluation for molecular-targeting therapy.},
 pages = {49749--49756},
 title = {Contrast media enhancement reduction predicts tumor response to presurgical molecular-targeting therapy in patients with advanced renal cell carcinoma},
 volume = {8},
 year = {2017}
}